Table 1.
Patient demographics.
| “Vaccination” cohort | Hybrid immunity1 | “Infection” cohort | |
|---|---|---|---|
| Number of individuals | 97 | 17 | 83 |
| Age (SD) | 50.2 (13.8) | 52.2 (9.3) | 46.6 (11.8) |
| Female/male (%female) | 67/30 (69.1) | 16/1 (94.1) | 72/11 (86.7) |
| Severity (WHO score) | |||
| 0 | 97 (100.0) | 4 (23.5) | 7 (8.4) |
| 1 | 9 (52.9) | 70 (84.3) | |
| 2 | 4 (23.5) | 6 (7.2) | |
| Individuals | |||
| 3 months | 97 | 17 | 83 |
| 10 months | 97 | 17 | 83 |
| Days after vaccination/positive PCR | |||
| at 3 months (SD) | 91.17 (1.38) | 91.59 (3.86) | 88.16 (5.21) |
| at 10 months (SD) | 296.3 (6.2) | 296.8 (6.0) | 293.8 (6.7) |
| New SARS-CoV-2 exposure between 3 and 10 months?² |
|||
| no new exposure | 75 (77.3) | 16 (94.1) | 83 (100.0) |
| breakthrough infection | 5 (5.2) | 1 (5.9) | |
| booster vaccination | 17 (17.5) | ||
1 Median time between positive PCR and administration of the first dose was 274 days (range:39-301).
2 Individuals who had a booster or breakthrough infection were excluded for the kinetics analyses of binding and surrogate neutralizing antibodies.